Examining the potential of rationally designed recombinant Infectious Bronchitis Virus as a vaccine against Infectious Bronchitis
View/ Open
Keep2020.pdf (10.26Mb)
Date
04/07/2020Item status
Restricted AccessEmbargo end date
04/07/2021Author
Keep, Sarah May
Metadata
Abstract
Infectious Bronchitis Virus (IBV) is a gammacoronavirus that is prevalent in poultry flocks
worldwide. Infection results in Infectious Bronchitis (IB), an economically important disease
characterised by snicking, rales, lethargy, loss of tracheal ciliary activity, reduced weight gain
and reduced egg production. Vaccination is commonly practiced using both live attenuated
and inactivated vaccines. Live attenuated vaccines are generated by serial passage of a
pathogenic field strain in embryonated chicken eggs; the molecular mechanism is unknown.
A fine balance needs to be achieved between the loss of pathogenic in vivo phenotype and
the retention of immunogenicity. Due to the unpredictability of the process and the time
required there is a drive to rationally design and rationally attenuate recombinant IBV (rIBV)
that can be subsequently utilised as live attenuated vaccines.
Vaccine induced protection is predominantly associated with the spike (S) glycoprotein,
which consists of two subunits, the immunodominant S1 and the highly conserved S2. Whilst
the latter is considered to be less immunogenic, it has been reported to play a role in
protective immunity. In this thesis rIBVs, based on the apathogenic rIBV, Beau-R, that
express heterologous S1 or S2 subunits BeauR-QX(S1), BeauR-M41(S1), BeauR-M41(S2),
or S glycoproteins, BeauR-M41(S) and BeauR-4/19(S) are investigated as vaccines against
either homologous or heterologous challenge. The rIBV expressing a heterologous S
glycoprotein, BeauR-M41(S) offered increased protection against homologous challenge as
defined by the retention of ciliary activity in comparison to those expressing heterologous S1
or S2 subunits, BeauR-M41(S1) and BeauR-M41(S2) respectively. The protection induced
however fell short of the standards set by the European Pharomopiea and further
investigation demonstrated that rIBV expressing heterologous S glycoproteins, BeauRM41(
S) and BeauR-4/91(S) could not protect against a heterologous QX challenge. One
possible explanation is the limited replication of the vaccine viruses in vivo. Investigation of
the Beau-R vaccine backbone determined that replication is temperature sensitive and highly
restricted at 41°C, the core body temperature of a chicken. As a consequence a rIBV based
on the laboratory strain M41-CK was subsequently investigated for its potential to act as a
vaccine backbone.